Cornerstone Capital, Inc. Viking Therapeutics, Inc. Transaction History

Cornerstone Capital, Inc.

$940 Million
Q4 2024

A detailed history of Cornerstone Capital, Inc. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Cornerstone Capital, Inc. holds 24,800 shares of VKTX stock, worth $755,904. This represents 0.11% of its overall portfolio holdings.

Number of Shares

24,800

Previous 29,770 16.69%

Holding current value

$755,904

Previous $1.88 Million 47.08%

% of portfolio

0.11%

Previous 0.18%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$38.28 - $78.03 $190,251 - $387,809	-4,970 Reduced 16.69%	24,800 $997,000
Q3 2024 Oct 30, 2024	SELL	$49.84 - $70.47 $208,331 - $294,564	-4,180 Reduced 12.31%	29,770 $1.88 Million
Q1 2024 May 01, 2024	SELL	$17.4 - $94.5 $1.32 Million - $7.18 Million	-76,025 Reduced 69.13%	33,950 $2.78 Million
Q4 2023 Feb 02, 2024	SELL	$9.24 - $19.64 $1,570 - $3,338	-170 Reduced 0.15%	109,975 $2.05 Million
Q2 2023 Aug 21, 2023	SELL	$14.84 - $24.79 $660,528 - $1.1 Million	-44,510 Reduced 28.78%	110,145 $1.79 Million
Q1 2023 May 15, 2023	BUY	$8.08 - $17.33 $123,624 - $265,149	15,300 Added 10.98%	154,655 $2.58 Million
Q4 2022 Feb 13, 2023	SELL	$2.72 - $9.4 $12,580 - $43,475	-4,625 Reduced 3.21%	139,355 $1.31 Million
Q3 2022 Oct 27, 2022	BUY	$2.55 - $3.89 $12,342 - $18,827	4,840 Added 3.48%	143,980 $392,000
Q2 2022 Aug 15, 2022	BUY	$2.11 - $3.15 $8,640 - $12,899	4,095 Added 3.03%	139,140 $402,000
Q1 2022 May 13, 2022	BUY	$3.0 - $4.88 $38,475 - $62,586	12,825 Added 10.49%	135,045 $405,000
Q3 2021 Nov 09, 2021	SELL	$5.58 - $7.04 $69,192 - $87,296	-12,400 Reduced 9.21%	122,220 $768,000
Q2 2021 Aug 13, 2021	BUY	$5.19 - $6.73 $5,060 - $6,561	975 Added 0.73%	134,620 $806,000
Q1 2021 May 17, 2021	BUY	$5.74 - $9.67 $29,733 - $50,090	5,180 Added 4.03%	133,645 $845,000
Q4 2020 Feb 12, 2021	BUY	$5.3 - $6.71 $15,900 - $20,130	3,000 Added 2.39%	128,465 $723,000
Q3 2020 Oct 27, 2020	BUY	$5.73 - $8.11 $62,181 - $88,009	10,852 Added 9.47%	125,465 $730,000
Q2 2020 Aug 14, 2020	BUY	$4.35 - $8.08 $12,345 - $22,931	2,838 Added 2.54%	114,613 $826,000
Q1 2020 May 15, 2020	SELL	$3.45 - $7.95 $462,372 - $1.07 Million	-134,021 Reduced 54.53%	111,775 $523,000
Q4 2019 Feb 10, 2020	SELL	$6.38 - $8.73 $14,859 - $20,332	-2,329 Reduced 0.94%	245,796 $1.97 Million
Q3 2019 Nov 13, 2019	SELL	$6.55 - $8.6 $6,550 - $8,600	-1,000 Reduced 0.4%	248,125 $1.71 Million
Q2 2019 Aug 14, 2019	BUY	$7.67 - $10.63 $33,172 - $45,974	4,325 Added 1.77%	249,125 $2.07 Million
Q1 2019 May 15, 2019	BUY	$7.58 - $9.94 $244,076 - $320,068	32,200 Added 15.15%	244,800 $2.43 Million
Q4 2018 Feb 11, 2019	BUY	$7.16 - $16.21 $232,549 - $526,484	32,479 Added 18.03%	212,600 $1.63 Million
Q3 2018 Nov 13, 2018	BUY	$9.7 - $19.65 $335,823 - $680,302	34,621 Added 23.79%	180,121 $3.14 Million
Q2 2018 Aug 13, 2018	BUY	$3.88 - $12.74 $228,338 - $749,749	58,850 Added 67.92%	145,500 $1.38 Million
Q4 2017 Feb 12, 2018	BUY	$1.74 - $4.34 $150,771 - $376,061	86,650	86,650 $352,000

Others Institutions Holding VKTX

# of Institutions

471

Shares Held

66.4M

Call Options Held

5.88M

Put Options Held

3.83M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $2.34B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cornerstone Capital, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cornerstone Capital, Inc. with notifications on news.

Account

Cornerstone Capital, Inc. Viking Therapeutics, Inc. Transaction History